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Abstract: 
 
Background: The purpose of this study was to determine the effect of 
postoperative radiotherapy (PORT) on recurrence and survival in patients with 
oral squamous cell carcinoma (OSCC) of intermediate risk of recurrence. 
Methods: Intermediate risk patients, defined as pT1, pT2, pN0 or pN1 with at 
least one adverse pathological feature, were identified form the head and 
neck databases of Liverpool Head and Neck Cancer Unit and Sydney Head 
and Neck Cancer Institute. Patients who had received surgery and PORT 
were case matched with patients who were treated by surgery alone based on 
pN, pT, margins and pathological features. 
Results: Of 1029 pT1T2 OSCC patients, 308 met the inclusion criteria and 90 
were matched into 45 pairs. There was a significant improvement in 
locoregional control with PORT (p=0.039), which was concentrated in the pN1 
subgroup (p=0.036), but not the pN0 subgroup (p=0.331). 
Conclusions: PORT significantly improves locoregional control for 
intermediate risk OSCC in the presence of nodal metastases.  
 
 
  
Introduction: 
 
Oral squamous cell carcinoma (OSCC) is usually treated by primary surgery.1 
The need for adjuvant therapy, in particular postoperative radiotherapy 
(PORT), is based on a synthesis of several clinical and pathological adverse 
features that increase the risk of locoregional failure. Patients at low risk of 
recurrence, where PORT can be safely omitted, are those with completely 
excised primary tumours less than 4cm in diameter (T1/T2) without adverse 
pathological features or nodal metastases. Locoregionally advanced tumours, 
particularly those with multiple nodal metastases, extracapsular spread (ECS) 
or positive margins have a high risk of recurrence and adjuvant therapy is 
essential. The remaining patients generally fall into an intermediate risk group. 
The decisions regarding the need for adjuvant therapy are based on 
institutional preferences, clinical acumen and patient preference and are 
supported only by low level contradictory evidence.2 This group includes node 
negative patients with close margins or adverse pathological features at the 
primary site, and patients with a single positive node without ECS.3 There is 
no consensus as to which of these patients will benefit from PORT4 and the 
potential for reduced recurrence must be balanced against the significant local 
toxicity5-7.  
A systematic review of the literature by the senior author (JSB) has 
highlighted how weak the evidence is for prescribing PORT for intermediate 
risk patients.2 The issue is further confounded by the prescription bias 
associated with retrospective cohort studies comparing outcomes for patients 
who have been treated with surgery followed by PORT and those treated by 
surgery alone. Patients treated by surgery and PORT often have worse 
outcomes than those treated by surgery alone2 reflecting the fact that patients 
who receive PORT generally have higher stage disease and more adverse 
pathological features.  
The prescription bias could be eliminated with a randomized trial but there 
would almost certainly be difficulties with recruitment. In the absence of data 
from a trial, we have attempted to minimize bias by case matching patients 
with intermediate risk who have received PORT with those treated by surgery 
alone. 
  
Methods: 
 
Patients with newly diagnosed OSCC between 1998 and 2013 were identified 
from the head and neck cancer databases of Liverpool Head and Neck Unit 
and the Sydney Head and Neck Cancer Institute (SHNCI). Patients fulfilling 
the following criteria were included: (1) OSCC treated by primary surgery 
including neck dissection; (2) pT1 or pT2; (3) pN0 or pN1 without ECS; (4) 
detailed pathological examination of the resection and neck specimens with 
deep and mucosal margin size recorded in mm; (5) at least one adverse 
pathological feature; (6) at least 1 year follow up. The exclusion criteria were 
(1) previously treated OSCC; (2) patients who did not have a neck dissection 
and therefore whose pN status was unknown; (3) patients with tumour 
reaching <1mm from the inked margin on histological examination; (4) 
patients with multiple positive nodes or ECS; (5) sites other than oral cavity 
SCC; (6) synchronous primary tumours; (7) patients treated with primary 
radiotherapy or neoadjuvant chemotherapy. Clinicopathological data was 
retrieved from the case notes and pathology reports.  
 
Patients who were treated by surgery and PORT were precisely case 
matched with patients treated by surgery alone. Lymphovascular invasion 
(LVI) and perineural invasion (PNI) were considered together to aid the 
matching process.  
The hierarchy of matching was as follows: 
1. pN category 
2. pT category 
3. Margin status  
4. Presence of PNI or LVI 
5. Tumour subsite 
6. Age of the patient 
7. Tumour differentiation  
 
For example, a 50 - 55 year old patient with pT2 pN0 tongue cancer with 
close margins, moderate differentiation and perineural invasion who was 
treated by surgery alone would be matched with a 50 – 55 yr old patient with a 
pT2 pN0 tongue cancer with close margins, moderate differentiation and PNI 
and/or LVI who was treated by surgery and PORT.  The investigator who 
performed the matching was blinded to outcome.  
 Margins were categorised as involved (<1mm); close (1-4.9mm) or clear 
(5mm or greater), as per Royal College of Pathologists (RCPath) guidelines8. 
Survival was calculated from the date of surgery to death taken from death 
certificate information tracked through the Office of National Statistics to 1st 
July 2015 for Liverpool patients and clinician follow up data for Sydney 
patients. Differences in survival and locoregional control were analysed using 
the log-rank test and p values of less than 0.05 were considered statistically 
significant.  
  
Results 
 
Of the 520 pT1T2 OSCC patients in the Liverpool Head and Neck Cancer 
database, 193 (117 males and 76 females) met the inclusion criteria. There 
were 27 patients treated by surgery and PORT (60Gy in 30 fractions), and 
166 were treated by surgery alone. Of these, 42 patients were successfully 
matched into 21 pairs. Of 509 pT1T2 OSCC patients in the SHNCI database, 
115 (66 males and 59 females) patients met the inclusion criteria. There were 
30 patients treated with surgery and PORT (60Gy in 30 fractions), and the 
remaining 95 were treated by surgery alone. Of these, 48 patients were 
matched into 24 pairs. 
In total, 45 matched pairs (90 patients) were included. The median age was 
60 (22.5-84.4) years. The median age of the Surgery and PORT group was 
58 (range 29.9-84.4) years and the median age for the Surgery alone group 
was 61 (range 22.5-84.4) years. There were 60 pN0 patients and 30 pN1 
patients. 77 patients had close margins and 35 had PNI/LVI. The mean 
number of matched criteria per matched pair was 5 (median 6; range 4-7). pN 
status and presence of PNI/LVI were matched in every case. pT status was 
matched in 43 of 45 cases. In the two cases were a pT1 was matched with a 
pT2, the matches were accepted on the basis that there was otherwise 
complete concordance (6 of 7 criteria). In one case a patient with a close 
margin (3mm) was matched with a patient with a clear margin. This match 
also otherwise had complete concordance of criteria. The characteristics of 
the patient cohort are shown in Table 1 and the characteristics of the matched 
pairs are shown in Table 2.  
Locoregional failure occurred in 22 patients (24.4%). This comprised 7 (7.8%) 
patients in the surgery and PORT group and 15 (16.7%) patients in the 
surgery alone group (p=0.039), shown in Figure 1. There was no difference in 
overall survival between the two groups (p=0.129) as shown in Figure 2. Of 
patients that recurred, salvage was attempted in 3 of 7 from the PORT group 
and 9 of 15 from the surgery alone group. Successful salvage was achieved 
in 2 (28.6%) surgery and PORT patients compared with 7 (46.7%) of surgery 
alone patients. 
The cohort was stratified by nodal stage (pN0 or pN1), and the presence of 
PNI/LVI. PORT was associated with improved locoregional control for the pN1 
group (p=0.036) as shown in Figure 3, but did not influence recurrence in the 
pN0 subgroup (p=0.331) as shown in Figure 4. PORT did not improve 
locoregional control for patients with PNI/LVI (p=0.965).   
The number of patients needed to be treated (NNT) with PORT in order to 
avoid one locoregional failure was 5.7, but this reduced to 3.0 for the pN1 
subgroup. 
 
  
Discussion: 
This study examines the effect of PORT on locoregional control and survival 
in patients with intermediate risk OSCC after primary surgery. The results 
show that PORT significantly improves locoregional control (p=0.039) over 
those treated by surgery alone. However, this benefit does not appear to 
translate directly into improved overall survival (p=0.129) and the effect was 
principally observed in patients with nodal involvement (pN1). The inability to 
demonstrate a survival difference may be in part due to the higher proportion 
of patients with recurrence successfully salvaged in the surgery alone group 
(7 of 15 compared with 2 of 7 in the surgery and PORT group). 
To our knowledge, this is the only case match study comparing outcomes for 
patients treated by primary surgery and PORT with those treated by primary 
surgery alone. The results are strengthened by the strict matching criteria and 
the utilization of two large head and neck databases from which to recruit 
patients. The Sydney Head and Neck Cancer Institute and the Liverpool Head 
and Cancer Unit have adopted very similar treatment paradigms in their 
approaches to intermediate risk OSCC with a preference for withholding 
PORT wherever possible. This is reflected in the small proportion of eligible 
patients who had received PORT (18.5%, 57/308). All specimens were 
reported by dedicated Head and Neck pathologists adhering to RCPath 
guidelines7 for processing and reporting oral cavity specimens. Patients 
treated prior to the introduction of these guidelines in 1998 were excluded. 
The inclusion only of patients who had a neck dissection allows us to 
accurately match patients based on their pathological nodal status and 
exclude high-risk patients with multiple nodes and/or ECS.  
We have attempted to eliminate the prescription bias associated with cohort 
studies comparing outcomes for patients receiving surgery and PORT with 
those treated by surgery alone by applying rigid matching criteria but must 
accept the reduced size of the final cohort associated with this.  
 
There is a paucity of high level evidence to base recommendations for 
prescription of PORT for OSCC6. Despite the widespread use of PORT since 
its introduction by Maccomb9 in 1957, only 3 randomised trials exist in the 
literature. All 3 examined the benefits of PORT in stage III/IV head and neck 
SCC but only one study was restricted to oral cavity disease10. The trials by 
Kokal11 and Rodrigo12 have conflicting results, and multiple weaknesses 
including mixed head and neck cohorts and small cohort size, limiting the 
relevance of their findings. The trial by Mishra was restricted to Stage III/IV 
buccal SCC and found improved overall and disease-free survival (p=0.005) 
for patients treated with surgery and PORT. This study is remarkable for the 
reported 3 year overall survival rates of 94% (surgery and PORT) and 84% 
(surgery alone), for stage III/IV buccal SCC which is often associated with 
poor prognosis13,14.  
Our findings conflict with previously published data from our units. Brown et 
al3 compared outcomes for unmatched cohorts of intermediate risk patients 
treated by surgery and PORT with those treated by surgery alone and found 
improved locoregional recurrence and survival (p=0.002) for patients in whom 
PORT was withheld. This data is confounded by the prescription bias 
associated with an unmatched comparative study of this nature. The patients 
in the PORT group are likely to have more advanced stage disease and more 
adverse pathological features15, explaining their poor outcome. Our results 
are consistent with those of Shrime et al16, who reported a survival advantage 
(p<0.001) for patients receiving PORT in a similar cohort (T1-2N1).  
 
The negative impact of the local toxicity associated with PORT on HRQOL is 
well documented3-5. Overall HRQOL declines during and after treatment but 
appears to recover to baseline levels after a year. However, physical function 
scores, especially those related to saliva and swallowing, remain persistently 
low4. This effect is worse for conventional radiotherapy compared with 
intensity-modulated radiotherapy (IMRT)17. Balancing the merits and toxicity of 
radiotherapy within an individual is critical to patient care. In this study 
approximately 6 patients would endure the side effects of radiotherapy in 
order to prevent one locoregional failure if the results were indiscriminately 
applied to all intermediate risk patients. Although this can be halved by only 
prescribing PORT to patients with nodal disease, other pathological features 
need to be carefully considered along with the patient’s preference. While the 
study did not demonstrate a difference in disease control for patients with 
PNI/LVI treated by surgery and those treated with surgery and PORT, it was 
not specifically designed to test this and the subgroup is too small to have 
confidence in the findings. 
 
Limitations 
While minimized, the prescription bias cannot be completely eliminated. 
Medical comorbidity strongly influences overall survival but quantifying and 
matching patients’ performance status would be very difficult. We have 
attempted to match the patients’ age as a surrogate for comorbidity but accept 
the limitations of this approach. Even within the rigid confines of our inclusion 
criteria, the intermediate risk patients are not a homogenous group, rather 
they are a heterogeneous group of patients with a gradation of recurrence 
risk. The potential for locoregional failure is certainly greater for a patient with 
a pT2N1 tumour with close margins and perineural spread than a pT1N0 
patient whose risk factor is close margins. Therefore some caution must be 
exercised in generalisation of the results. 
 
Conclusion 
PORT is associated with improved locoregional control in intermediate risk 
OSCCC patients. Despite this, it appears to reduce the chances of successful 
salvage, thereby negating any expected survival benefit. The positive affect 
appears to be concentrated in the pN1 patients and is much less clear for 
node negative patients. This study supports the use of PORT for node 
positive OSCC patients. 
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Table 1: Cohort characteriestics: Number (percentage) 
 Overall Surgery + PORT Surgery alone 
Mean age:  60.0   58.0   61.0  
Gender:    
Male 54 (60%) 29 (32.2%) 25 (27.8%) 
Female 36 (40%) 16 (17.8) 20 (22.2%) 
Length of follow 
up (yrs): 
3.7  4.1 3.2 
Site:    
Tongue 56 (62.2%) 28 (31.1%) 28 (31.1%) 
Floor of mouth 19 (21.1%) 9 (10.0%) 10 (11.1%) 
Buccal mucosa 12 (13.3%) 6 (6.65%) 6 (6.65%) 
Hard palate or 
RMT 
3 (3.3%) 2 (2.2%) 1 (1.1%) 
pT stage    
pT1 24 (26.6%) 11 (12.2%) 13 (14.4%) 
pT2 66 (73.4%) 34 (37.8%) 32 (35.6%) 
pN stage    
pN0 60 (66.7) 30 (33.35%) 30 (33.35%) 
pN1 30 (33.3) 15 (16.65%) 15 (16.65%) 
Margins:    
Clear 13 (14.4%) 7 ( 7.8%) 6 (6.6%) 
Close  77 (85.5%) 
 
38 (42.2%) 39 (43.3%) 
PNI 30 (33.3%) 15 (16.65%) 15 (16.65%) 
LVI 9 (10.0%) 4 (4.4%) 5 (5.6%) 
PNI or LVI or 
both 
35 (38.9%) 
 
17 (18.9%) 18 (20.0%) 
Tumour 
differentiation: 
   
Well 15 (16.6%) 6 (6.6%) 9 (10.0%) 
Moderate 57 (63.3%) 28 (31.1%) 29 (32.2%) 
Poor 13 (14.4%) 8 (8.89%) 5 (5.55%) 
Unknown 5 (5.55%) 3 (3.33%) 2 ( 2.22%) 
 
  
 Table 2: Characteristics of matched pairs 
 
Characteristics: No. of matched 
pairs 
(Number of patients) 
  
pT1pN0, close margins, No PNI/LVI 5 (10) 
pT1pN0, close margins, PNI/LVI 2 (4) 
pT1/T2pN0, close margins, PNI/LVI 2 (4) 
pT2pN0, clear margins, No PNI/LVI 1 (2) 
pT2pN0, clear margins, PNI/LVI 2 (4) 
pT2pN0, clear/close margins, PNI/LVI 1 (2) 
pT2pN0, close margins, No PNI/LVI 10 (20) 
pT2pN0, close margins, PNI/LVI 7 (14) 
pT1pN1, clear margins, PNI/LVI 1 (2) 
pT1pN1, close margins, No PNI/LVI 3 (6) 
pT2pN1, clear margins, No PNI/LVI 1 (2) 
pT2pN1, clear margins, PNI/LVI 1 (2) 
pT2pN1, close margins, No PNI/LVI 7 (14) 
pT2pN1, close margins, PNI/LVI 2 (4) 
TOTAL: 45 (90) 
 
  
Figure 1: Kaplan Meier curve of locoregional recurrence: 
 
 
p=0.039 
 
 
Figure 2: Kaplan Meier curves of overall survival: 
 
p=0.129 
45 34 26 19 13 11 8
45 39 35 27 21 15 13
Numbers at Risk
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5 6
proportion
Time(years)
no	RTRT
45 40 30 25 19 17 10
45 41 37 29 23 16 13
Numbers at Risk
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5 6
proportion
Time(years)
no	RTRT
 Figure 3: Kaplan Meier curves of locoregional control for pN1 disease 
 
p=0.036 
Figure 4: Kaplan Meier curves of locoregional control for pN0 disease 
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